36 results about "B-cell receptor" patented technology

An antibody against respiratory syncytial virus (RSV) and / or human metapneumovirus (HMPV) is described herein. The antibody includes binding domains from anti-idiotypic monoclonal antibodies (ai-mAbs) that bind an RSV neutralizing antibody VH3-21 / VL1-40 presented as B cell receptors (BCRs). The antibodies can be used as a vaccine to selectively elicit antibodies capable of neutralizing RSV and / or HMPV without a need for somatic mutation. The vaccines are particularly useful to treat and / or reduce the risk of RSV and / or HMPV infection in infants.

To provide a gene testing method and a gene testing kit for analyzing a variable region of a TCR or a BCR in single-cell analysis.SOLUTION: A method including a step of capturing mRNA eluted from a single cell using an RT probe immobilized on a solid-phase surface and including a common sequence, a cell identification barcode, a first molecular identification barcode, and an oligo(dT) sequence, a step of performing a reverse transcription reaction in a reverse transcription reaction solution containing a TSO using the mRNA as a template to generate cDNA having a sequence added to a 3' end, a step of degrading the mRNA, a step in which a primer for inserting a second molecular identification barcode binds to a constant region adjacent to a variable region of a TCR or a BCR and includes the second molecular identification barcode, a step of ligating cDNA extended from the primer with a ligase, a step of amplifying a fragment including the second molecular identification barcode and the variable region of the TCR or the BCR using a primer, a step of performing sequence analysis, and a step of associating sequences.SELECTED DRAWING: Figure 2

The invention provides a rabbit-source BCR sequence primer group based on high-throughput single cell V (D) J sequencing and application of the rabbit-source BCR sequence primer group. The primer group comprises a specific nested PCR (Polymerase Chain Reaction) primer pair (the sequence is as shown in SEQ ID NO.1-12) aiming at a rabbit BCR heavy chain (IgA / IgE / IgG / IgM) and a light chain (IgK / IgL). Through microfluid single-cell separation, nested PCR amplification and high-throughput sequencing, the naturally paired rabbit BCR full-length V (D) J sequence can be efficiently obtained. According to the rabbit-derived BCR sequence sequencing primer provided by the invention, B cell receptor library information of different tissue sources can be quickly and efficiently obtained. According to the method, paired antibody sequence information can be specifically obtained, B cell response diversity after rabbit immunization vaccine or pathogen infection can be better known, and important data support is provided for design, optimization, effect evaluation and the like of biological products.

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of B cell receptor. In some cases, determining a sequence of B cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.

Provided are: an agent for damaging and / or removing cell receptor (BCR)-expressing cells; and a therapeutic agent and a pharmaceutical composition for autoimmune disease each containing the agent. The agent for damaging and / or removing BCR-expressing cells comprises: a group capable of selectively binding to at least one selected from the group consisting of a BCR recognizing a self-antigen and an antibody recognizing the self-antigen; and a substance having a cytotoxic group.

The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The present disclosure relates generally to methods of uniquely labeling or barcoding molecules within immune cells such as B cells, or within nuclei derived therefrom. The present disclosure also relates to kits for uniquely labeling molecules within immune cells such as B cells, or within nuclei derived therefrom. In particular, the methods and kits may relate to the labeling of RNAs and / or cDNA encoding B cell receptors (BCRs) within such cells or nuclei.

The invention provides an EBV susceptible 293T cell capable of simultaneously expressing an epidermal cell receptor EphA2 and a cleavage replication key protein RTA, and an EBV susceptible BJAB cell capable of simultaneously expressing a B cell receptor CD21 and a cleavage replication key protein ZTA, so that the infectivity of the cells on EBV is remarkably improved. The EBV infection titer of the cell line disclosed by the invention is more than three times that of normal control under the same condition. The EBV susceptible cells are of great significance to research of EBV infection mechanisms, screening of antiviral drugs and research and development of vaccines.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present invention provides a genetic test method and a genetic test kit for immune cells in blood. Specifically, the present invention provides a genetic test method and a genetic test kit for analyzing a variable region of a T cell receptor (TCR) or a B cell receptor (BCR) in a single cell analysis technique.

This invention is directed to genetically engineered B cells, wherein the B cell expresses and bears on its surface a chimeric B cell receptor, and wherein the genetically engineered B cell further expresses and secretes an antibody or cytokine.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

This invention provides EBV-susceptible 293T cells that simultaneously express the epidermal cell receptor EphA2 and the key protein RTA for lysis and replication, and EBV-susceptible BJAB cells that simultaneously express the B cell receptor CD21 and the key protein ZTA for lysis and replication, significantly enhancing the infectivity of these cells for EBV. The EBV infection titer of the cell lines of this invention is more than three times that of the normal control under the same conditions. These EBV-susceptible cells are of great significance for studying the mechanism of EBV infection, screening antiviral drugs, and developing vaccines.

Disclosed herein is a pipeline to identify variable chains (VCR), which encompass T cell receptors (TCRs) and B cell receptors (BCRs), that recognize epitopes in their low affinity using a bioinformatic statistical method with 10× data that encompasses both preprocessing and identification of antigen-specific VCRs. Also disclosed are methods for treating subjects having viral infections or cancer, the methods comprising administering antibodies from B cells transduced with antigen-specific BCRs and / or modified allogenic T cells transduced with antigen-specific TCRs identified through use of the pipeline.

The present disclosure relates to methods for testing the health of a subject's immune system and treating the subject based on the condition of the immune system. In particular, disclosed herein is a method comprising the steps of obtaining a sample of blood from the subject, reverse transcribing DNA from RNA in the sample; amplifying all seven chains of T and B cell receptors in the DNA sample using multiplex PCR to form amplicons; sequencing the amplicons to generate a sequencing library; identifying nodetypes, clonotypes, v genes, d genes, and j genes and corresponding read counts in the sequencing library; performing the foregoing steps using two or more healthy samples to form a consensus reference pool; identifying the number of nodetypes associated with each V gene sequence in the consensus reference pool and in the subject's sequencing library; comparing the number of nodetypes for each V gene in the consensus reference pool and the subject's sequencing library; and treating the subject if the number of nodetypes is significantly less than the number of nodetypes for V genes in the consensus reference pool. The disclosed method is able to identify gaps in an individual's immune system and treat that individual to improve the diversity of the individual's immune response.

Proposed are a foot-and-mouth disease vaccine composition including recombinant foot-and-mouth disease viruses and an antigen isolated and purified from the viruses. In the early stages of vaccination, a humoral immune response is simultaneously induced through the induction of a robust cellular immune response, while in the presence of maternally-derived antibodies (MDAs), B cell receptors are stimulated. Through this, it is possible to provide the vaccine composition that enables active immunity and overcomes the interference of the maternally-derived antibodies and to provide a method of preventing or treating foot-and-mouth diseases using the same composition.

The application discloses a kind of for preventing Bungowenia virus Polyepitope fusion protein, gene, vaccine and preparation method thereof, belong to biological medicine technical field.The Polyepitope fusion protein for preventing Bungowenia virus provided in the application is obtained in series by E. coli outer membrane anchoring protein ClyA, four MHC I class restricted T cell epitopes, four MHC II class restricted T cell epitopes, two B cell epitopes and BALB / c mouse immunoglobulin Fc fragment.The vaccine of the application is prepared by high-pressure homogenization process to obtain the engineered artificial nanovesicle (E-aBNV) with high-density surface display antigen array.The E-aBNV utilizes itself pathogen-associated molecular pattern to provide "self-adjuvant" effect, can efficiently activate B cell receptor and promote antigen cross-presentation, thereby synergistically inducing high level of neutralizing antibody and Th1-biased cellular immunity, which can effectively block the infection of Bungowenia virus to host cell.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

To provide methods for preparing NGS library to enable simultaneous analysis of T cell receptor (TCR) or B cell receptor (BCR) repertoire and gene expression.SOLUTION: The disclosed method comprises the steps of: (1) capturing mRNA eluted from cell using an RT probe immobilized on a solid phase surface; (2) generating 1st cDNA using the captured mRNA as a template; (3) removing excess RT probe not contributed to the 1st cDNA synthesis; (4) conducting PCR amplification using the 1st cDNA as a template; (5) forming circular DNA on the PCR amplified product using a ligase; (6) conducting PCR amplification using the circular DNA as a template; (7) separating a portion of the PCR amplified product obtained in (4) for gene expression analysis and amplifying at least partial region of the subject genes by PCR.SELECTED DRAWING: Figure 2

The present disclosure provides methods, compositions, kits, and systems useful in the determination and evaluation of the immune repertoire. In one aspect, target-specific primer panels provide for the effective amplification of nucleic acid sequences of murine T cell receptor and / or B cell receptor chains with improved sequencing accuracy and resolution over the repertoire. Variable regions associated with the immune cell receptor are resolved to effectively portray clonal diversity of a biological sample and / or differences associated with the immune cell repertoire of a biological sample.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.

The invention relates to a single-cell multi-omics detection kit and application thereof. According to the single-cell multi-omics detection kit designed by the invention, a single-chain cell nucleic acid label with template conversion and connection capabilities is utilized, so that RNA and DNA in the same cell can be subjected to cell labeling at the same time, the cost is controllable, the process is simple, the kit has the characteristic of high throughput, thousands of single cells can be detected at the same time, and in addition, the kit has a good application prospect. By utilizing 5'transcriptome characteristics, variable VDJ information containing T / B cell receptors and gRNA sequence information can be synchronously analyzed, and the molecular action mechanism of cells can be analyzed in more omics modes.

The invention discloses a tumor nano vaccine for targeting B cells as well as a preparation method and application of the tumor nano vaccine. According to the tumor vaccine, on the basis of tumor cell membrane vesicles retaining tumor antigens, oligonucleotide of an immunologic adjuvant CpG motif and an anti-CD40 antibody are modified on the vesicles through a small molecule chemical cross-linking agent, and the tumor nano vaccine is obtained. According to the vaccine, an activation signal is provided for a B cell through combination of an antigen and a B cell receptor, combination of CpG and a Toll-like receptor and combination of an anti-CD40 antibody and CD40. According to the tumor nano vaccine, on one hand, the immune response of anti-tumor cells can be promoted by enhancing the antigen presentation capability of B cells; on the other hand, B cells can be induced to be differentiated into plasma cells, tumor antigen specific antibodies are secreted, and anti-tumor humoral immune response is mediated. The tumor vaccine disclosed by the invention can be used for comprehensively activating anti-tumor immune response and has a good application prospect in tumor treatment.

Disclosed herein include systems, methods, compositions, and kits for immune repertoire profiling. There are provided, in some embodiments, primer panels enabling the determination of the nucleotide sequence of the complete variable region of nucleic acids encoding mouse B cell receptor (BCR) and T cell receptor (TCR) polypeptides. In some embodiments, the method comprises single cell transcriptomic analysis.

Provided herein are methods for determining a sequence of a double stranded DNA molecule of an immune cell receptor (e.g., T cell receptor, B cell receptor).

B cells engineered to express B cell receptors targeting a HER2 antigen and compositions and methods for use or preparation thereof.

The present invention relates to: a method for simultaneously preparing an NGS library for T receptor (TCR) or B cell receptor (BCR) repertoire analysis and an NGS library for gene expression analysis; and a method for simultaneously analyzing T cell receptor (TCR) or B cell receptor (BCR) repertoire diversity and gene expression.